Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07624435

Conventional Lead Opposed to Novel ECG (CLONE)

To blindly assess, beat-by-beat, standard ECG intervals (QRS intervals, PQ intervals, and P wave durations) of paired standard lead v4 with paired HeartWatch signals over 20 to 30 seconds of noise-free data.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

ECG Monitoring

Age range

22 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Calgary, Calgary, Alberta, Canada

Loading trial locations.

About this study

This proof-of-concept study will enroll volunteers undergoing serial conventional 12-lead ECG rhythm strips who agree to wear a HeartWatch and use a Kardia mobile during those recordings.

The HeartWatch data will not be used for clinical decision-making. Rhythm strips from conventional 12-lead ECG recordings and the HeartWatch recordings will be obtained in volunteers in supine and standing positions and with the device placed in the recommended and in non-recommended positions (i.e., internally and externally rotated in keeping with the observed malposition identified in human factors testing environments (one inch or 2.5 cm; HelpWear, data on file).

Rhythm strips from serial 10-sec, 12-lead recordings will be obtained to allow for beat-by-beat comparisons of ECG intervals over the 20 to 30 seconds of noise free data. Specifically, the intervals from continuous v4 beats with paired continuous HeartWatch beats and the intervals from continuous lead I beats with paired continuous Kardia beats.

Since the HeartWatch is not intended to be used for evaluation of the ST segment or the QT interval, the comparison of the HeartWatch to standard lead v4 will exclude QT assessment.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 22 years of age at time of the conventional ECG recording
  • Willing to participate in the study
  • Able to follow the protocol

Exclusion criteria

  • Known allergy to the electrodes used for a conventional ECG
  • Known allergy to any component of the HeartWatch
  • Known allergy to any component of the Kardia system
  • Inability to wear the HeartWatch on the left arm due to pre-existing medical condition (e.g., functional AV fistula in left arm, prior carcinoma with lymph node dissection or lymphedema, known blood clot or recurrent blood clots in left arm, chronic neuropathic pain in left arm, …)
  • Dextrocardia
  • Implanted functional Pacemaker of Defibrillator
  • Left upper arm circumference < 22 cm or > 45 cm

Treatment and study plan

ECG signals collection

Device

A Health-Canada and FDA-approved 12-lead ECG system (GE Healthcare, MAC 5500 or equivalent) will be used to collect the 10-sec digital rhythm strips in the noted supine and standing positions.

A total of twenty-four (24) recordings, four from each of position, will be collected from each consenting participant:

  • Supine with HeartWatch in the recommended position
  • Standing with HeartWatch in the recommended position
  • Supine with HeartWatch in a one inch (2.5 cm) externally rotated position
  • Supine with HeartWatch in a one inch (2.5 cm) internally rotated position
  • Supine while collecting a 30-sec Kardia recording
  • Standing while collecting a 30-sec Kardia recording

Other names: Standard 12 lead ECG, Kardia ECG, Heartwatch ECG

Primary outcomes

  1. Standard ECG and HeartWatch interval duration assessment in standard position

    Time frame: The data for this outcome will be collected for each participant in their testing visit. All data is then assessed within two weeks of the data collection testing visit.

    The three co-primary efficacy endpoints for this study are beat-by-beat QRS intervals, PQ intervals, and P wave durations in continuous ECG (HeartWatch vs. lead v4 of a standard 12-lead ECG) in a supine position with the HeartWatch in the standard location.

Secondary outcomes

  1. ECG interval assessment with the heart watch and the 12 Lead ECG in non traditional positions.

    Time frame: The data for this outcome will be collected for each participant in their testing visit. All data is then assessed within two weeks of the data collection from their testing visit.

    Secondary efficacy endpoints for this study are beat-by-beat QRS intervals, PQ intervals, and P wave durations in continuous ECG (HeartWatch vs. lead v4 of a standard 12-lead ECG) in a:

    • standing position with the HeartWatch in the standard location;
    • supine position with the HeartWatch in a one inch (2.5 cm) externally rotated;
    • supine position with the HeartWatch in a one inch (2.5 cm) internally rotated.

Other outcomes

  1. 12 Lead ECG and Kardia signal duration analysis from supine and standing positions

    Time frame: The data for this outcome will be collected for each participant in their testing visit. All data is then assessed within two weeks of the data collection from their testing visit.

    Exploratory endpoints for this study, for comparative purposes, are beat-by-beat QRS intervals, PQ intervals, and P wave durations in continuous ECG (Kardia system vs. lead I of a standard 12-lead ECG) in supine and standing positions.

  2. Device related adverse events.

    Time frame: Adverse events will be collected and assessed from all data collection visits immediately following every data collection visit. All adverse events will be followed until resolved or for up to 30 days after the event.

    The safety endpoint for this study is the incidence of device-related adverse events.

Sponsors and collaborators

Lead sponsor

HelpWear Inc.

Industry

Registry information

Official study title

Conventional Lead Opposed to Novel ECG

Acronym: CLONE

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jun 3, 2026
Registry last updated
Jun 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.